Literature DB >> 27889185

NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.

Haiming Xu1, Daria G Valerio2, Meghan E Eisold2, Amit Sinha2, Richard P Koche2, Wenhuo Hu3, Chun-Wei Chen4, S Haihua Chu4, Gerard L Brien4, Christopher Y Park3, James J Hsieh3, Patricia Ernst5, Scott A Armstrong6.   

Abstract

The nucleoporin 98 gene (NUP98) is fused to a variety of partner genes in multiple hematopoietic malignancies. Here, we demonstrate that NUP98 fusion proteins, including NUP98-HOXA9 (NHA9), NUP98-HOXD13 (NHD13), NUP98-NSD1, NUP98-PHF23, and NUP98-TOP1 physically interact with mixed lineage leukemia 1 (MLL1) and the non-specific lethal (NSL) histone-modifying complexes. Chromatin immunoprecipitation sequencing illustrates that NHA9 and MLL1 co-localize on chromatin and are found associated with Hox gene promoter regions. Furthermore, MLL1 is required for the proliferation of NHA9 cells in vitro and in vivo. Inactivation of MLL1 leads to decreased expression of genes bound by NHA9 and MLL1 and reverses a gene expression signature found in NUP98-rearranged human leukemias. Our data reveal a molecular dependency on MLL1 function in NUP98-fusion-driven leukemogenesis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hox gene; NUP98 fusion; leukemia; mixed lineage leukemia 1; non-specific lethal histone-modifying complexes

Mesh:

Substances:

Year:  2016        PMID: 27889185      PMCID: PMC5501282          DOI: 10.1016/j.ccell.2016.10.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  51 in total

Review 1.  MLL: a histone methyltransferase disrupted in leukemia.

Authors:  Jay L Hess
Journal:  Trends Mol Med       Date:  2004-10       Impact factor: 11.951

2.  NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.

Authors:  Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Marta Pratcorona; Saman Abbas; Jenny E Kuipers; Janneke F van Galen; H Berna Beverloo; Edwin Sonneveld; Gert-Jan J L Kaspers; Jan Trka; Andre Baruchel; Martin Zimmermann; Ursula Creutzig; Dirk Reinhardt; Rob Pieters; Peter J M Valk; C Michel Zwaan
Journal:  Blood       Date:  2011-08-02       Impact factor: 22.113

3.  Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes.

Authors:  Maya Capelson; Yun Liang; Roberta Schulte; William Mair; Ulrich Wagner; Martin W Hetzer
Journal:  Cell       Date:  2010-02-05       Impact factor: 41.582

4.  Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex.

Authors:  Yong Cai; Jingji Jin; Selene K Swanson; Michael D Cole; Seung Hyuk Choi; Laurence Florens; Michael P Washburn; Joan W Conaway; Ronald C Conaway
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

5.  In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.

Authors:  Anmaar M Abdul-Nabi; Enas R Yassin; Nobish Varghese; Hrishikesh Deshmukh; Nabeel R Yaseen
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

Review 6.  Structure, dynamics and function of nuclear pore complexes.

Authors:  Maximiliano A D'Angelo; Martin W Hetzer
Journal:  Trends Cell Biol       Date:  2008-09-09       Impact factor: 20.808

7.  Monoclonal antibodies recognize gly-leu-phe-gly repeat of nucleoporin nup98 of tetrahymena, yeasts, and humans.

Authors:  Masaaki Iwamoto; Haruhiko Asakawa; Chizuru Ohtsuki; Hiroko Osakada; Takako Koujin; Yasushi Hiraoka; Tokuko Haraguchi
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2013-04

8.  Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors:  Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

9.  NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.

Authors:  Gang G Wang; Ling Cai; Martina P Pasillas; Mark P Kamps
Journal:  Nat Cell Biol       Date:  2007-06-24       Impact factor: 28.824

10.  Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger.

Authors:  Gang G Wang; Jikui Song; Zhanxin Wang; Holger L Dormann; Fabio Casadio; Haitao Li; Jun-Li Luo; Dinshaw J Patel; C David Allis
Journal:  Nature       Date:  2009-06-11       Impact factor: 49.962

View more
  56 in total

1.  Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Authors:  Jarno L Kivioja; Angeliki Thanasopoulou; Ashwini Kumar; Mika Kontro; Bhagwan Yadav; Muntasir M Majumder; Komal K Javarappa; Samuli Eldfors; Juerg Schwaller; Kimmo Porkka; Caroline A Heckman
Journal:  Leukemia       Date:  2018-12-19       Impact factor: 11.528

2.  NUP98 and KMT2A: usually the bride rather than the bridesmaid.

Authors:  Alexandre Fagnan; Thomas Mercher
Journal:  Haematologica       Date:  2020-07       Impact factor: 9.941

3.  Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.

Authors:  Liat Goldberg; Sheryl M Gough; Fan Lee; Christine Dang; Robert L Walker; Yuelin J Zhu; Sven Bilke; Marbin Pineda; Masahiro Onozawa; Yang Jo Chung; Paul S Meltzer; Peter D Aplan
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 5.006

Review 4.  The roles of the nuclear pore complex in cellular dysfunction, aging and disease.

Authors:  Stephen Sakuma; Maximiliano A D'Angelo
Journal:  Semin Cell Dev Biol       Date:  2017-05-12       Impact factor: 7.727

5.  Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities.

Authors:  Sophie Cardin; Mélanie Bilodeau; Mathieu Roussy; Léo Aubert; Thomas Milan; Loubna Jouan; Alexandre Rouette; Louise Laramée; Patrick Gendron; Jean Duchaine; Hélène Decaluwe; Jean-François Spinella; Stéphanie Mourad; Françoise Couture; Daniel Sinnett; Élie Haddad; Josette-Renée Landry; Jing Ma; R Keith Humphries; Philippe P Roux; Josée Hébert; Tanja A Gruber; Brian T Wilhelm; Sonia Cellot
Journal:  Blood Adv       Date:  2019-11-12

Review 6.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

7.  POM121 is a novel marker for predicting the prognosis of laryngeal cancer.

Authors:  Ruihua Zhao; Genxiong Tang; Tengqi Wang; Lingli Zhang; Wei Wang; Qiangfang Zhao; Kun Zhao
Journal:  Histol Histopathol       Date:  2020-10-05       Impact factor: 2.303

8.  CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia.

Authors:  Johannes Schmoellerl; Inês Amorim Monteiro Barbosa; Thomas Eder; Tania Brandstoetter; Luisa Schmidt; Barbara Maurer; Selina Troester; Ha Thi Thanh Pham; Mohanty Sagarajit; Jessica Ebner; Gabriele Manhart; Ezgi Aslan; Stefan Terlecki-Zaniewicz; Christa Van der Veen; Gregor Hoermann; Nicolas Duployez; Arnaud Petit; Helene Lapillonne; Alexandre Puissant; Raphael Itzykson; Richard Moriggl; Michael Heuser; Roland Meisel; Peter Valent; Veronika Sexl; Johannes Zuber; Florian Grebien
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 9.  Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis.

Authors:  Weiwei Yang; Patricia Ernst
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

Review 10.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.